MYASTHENIA GRAVIS (MG)
Clinical trials for MYASTHENIA GRAVIS (MG) explained in plain language.
Never miss a new study
Get alerted when new MYASTHENIA GRAVIS (MG) trials appear
Sign up with your email to follow new studies for MYASTHENIA GRAVIS (MG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-phase study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target …
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated May 26, 2026 04:20 UTC
-
New injection targets tough autoimmune diseases
Disease control Recruiting nowThis early study tests an experimental injection called EVM18001 in 12 people with active, hard-to-treat lupus, myasthenia gravis, or scleroderma. The main goals are to check safety and find the right dose. Researchers will also look at how the drug works in the body and if it he…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: NA • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Engineered immune cells take aim at debilitating brain and nerve diseases
Disease control Recruiting nowThis early-phase study is testing a new treatment called universal CAR-T cells (RD06-05) in up to 36 adults with relapsing or refractory multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis. The therapy uses speciall…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called QH103 in up to 6 people with relapsed or hard-to-treat autoimmune diseases like multiple sclerosis and myasthenia gravis. The therapy uses specially engineered immune cells to target and calm the overactive immune system. The…
Matched conditions: MYASTHENIA GRAVIS (MG)
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 22, 2026 13:55 UTC